Company Overview
CDT Equity Inc. operates as a clinical-stage specialty biopharmaceutical company focused on developing pharmaceutical products designed to address unmet medical needs within the healthcare sector. The company specifically targets therapeutic areas such as autoimmune diseases and idiopathic male infertility, with its pipeline currently featuring AZD1656, which has completed Phase I trials for the treatment of type 2 conditions. This biotechnology entity functions with a very small operational footprint, employing only six individuals while maintaining a total market capitalization of $37.07 million. The combination of a relatively modest market cap and the absence of reported annual revenue in the provided data indicates that the company is in an early development stage where capital is primarily allocated toward research and development rather than commercial scale-up.
Financial Health
The financial statements for CDT Equity Inc. report a net income of $-20,305,000 over the trailing twelve months, while EBITDA stands at $-16,895,000, highlighting a significant cost structure where operating expenses substantially exceed any revenue generation. Although the specific revenue figure is not available in the current dataset, the substantial negative net income relative to the reported free cash flow of $-16,540,875 suggests that cash burn is occurring at a rate consistent with the reported losses. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated positive revenue to establish traditional profitability margins typical of mature pharmaceutical firms. The balance sheet shows the company holds $3.84 million in cash against $1.88 million in debt, resulting in a debt-to-equity ratio of 43.83, which reflects a leveraged position despite the lack of interest-bearing debt pressure on current operations. Liquidity for the short term appears manageable with a current ratio of 1.66, suggesting the company possesses sufficient current assets to cover its current liabilities without immediate distress. Furthermore, the return on equity is listed as N/A due to the lack of positive retained earnings, while the return on assets is -207.0%, revealing that the asset base is currently generating negative returns for shareholders.
Valuation Assessment
Valuation multiples for CDT Equity Inc. include a P/E ratio (TTM) and forward P/E that are both listed as N/A, reflecting the absence of positive earnings required to calculate traditional price-to-earnings metrics. The price-to-book ratio is 0.09, which indicates that the stock is trading at a significant discount relative to its book value, a common characteristic for clinical-stage biotechs with no commercial revenue. Additionally, the price-to-sales ratio is N/A, and the EV/EBITDA stands at 0.09, suggesting that valuation is being assessed primarily on asset backing rather than cash flow generation or sales growth. Regarding price action, the 52-week high is recorded at $168.00 and the 52-week low is $0.44, placing the current valuation in a highly compressed range relative to the peak price. The beta value is 1.81, indicating that the stock's price volatility is significantly higher than the broader market, with movements amplified by the high-risk nature of the clinical development stage.
Growth & Income
Growth metrics for revenue and earnings are both listed as N/A, which implies that the company is not yet in a commercialization phase where year-over-year growth rates are meaningful or calculable. Since the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, meaning all available cash and equity value are retained to fund ongoing research and development activities. The absence of a dividend program is standard for clinical-stage biopharmaceutical companies that must reinvest earnings into their pipeline to reach market approval rather than providing income to investors. Consequently, the overall growth and income profile is defined by potential future value creation from the AZD1656 pipeline and asset value retention, rather than current cash flow returns or income distribution.